FDA's Off-Label Delay Not Enough For Big Drugmakers

The U.S. Food and Drug Administration’s delay of controversial new policies on off-label promotion doesn’t go far enough and should be followed by quick action to erase uncertainty about acceptable marketing...

Already a subscriber? Click here to view full article